7-((4aS,7aS)-1-(2,2-bis(dimethylphosphono)ethyl)-octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid | 925684-39-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-((4aS,7aS)-1-(2,2-bis(dimethylphosphono)ethyl)-octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid
• 英文别名: 7-[(4aS,7aS)-1-[2,2-bis(dimethoxyphosphoryl)ethyl]-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
• CAS: 925684-39-5
• 化学式: C₂₇H₃₈FN₃O₁₀P₂
• 分子量: 645.559
• InChiKey: SDQNTHKJKGQNEU-HRAATJIYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  144
• 氢给体数：
  1
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  7-((4aS,7aS)-1-(2,2-bis(dimethylphosphono)ethyl)-octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid 在 三甲基溴硅烷 、 sodium hydroxide 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以59%的产率得到7-((4aS,7aS)-1-(2,2-bisphosphonoethyl)-octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections

  摘要：

  本发明涉及磷酸化氟喹诺酮及其抗菌类似物，以及使用这些化合物的方法。这些化合物可用作抗生素，用于预防和/或治疗骨骼和关节感染，特别是用于预防和/或治疗骨髓炎。

  公开号：

  US20080287396A1
• 作为产物：
  描述：

  1,1-Bis(dimethoxyphosphoryl)-2-methoxyethane 在 4-二甲氨基吡啶 对甲苯磺酸 作用下， 以 氯仿 为溶剂， 反应 3.5h， 生成 7-((4aS,7aS)-1-(2,2-bis(dimethylphosphono)ethyl)-octahydropyrrolo[3,4-b]pyridin-6-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections

  摘要：

  本发明涉及磷酸化氟喹诺酮及其抗菌类似物，以及使用这些化合物的方法。这些化合物可用作抗生素，用于预防和/或治疗骨骼和关节感染，特别是用于预防和/或治疗骨髓炎。

  公开号：

  US20080287396A1

文献信息

• Ketolide Derivatives as Antibacterial Agents
  申请人：Das Biswajit

  公开号：US20080287376A1

  公开（公告）日：2008-11-20

  The present invention provides ketolide derivatives, which can be used as antibacterial agents. In particular, compounds described herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp. Chlamydia spp., Mycoplasm, Legionella spp., Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebaclerium, Bacillus or Enterobactericeae. Also provided are processes for preparing such ketolide derivatives, pharmaceutical compositions thereof, and methods of treating bacterial infections.

  本发明提供了酮烯类衍生物，可用作抗菌剂。具体而言，本文所描述的化合物可用于治疗或预防由革兰氏阳性菌、革兰氏阴性菌或厌氧菌引起或促成的疾病，更具体地针对例如葡萄球菌、链球菌、肠球菌、衣原体、流感嗜血杆菌属、沙眼衣原体属、支原体、军团菌属、分枝杆菌、幽门螺杆菌、梭状芽孢杆菌、拟杆菌属、芽孢杆菌或肠杆菌科。还提供了制备此类酮烯类衍生物的方法、其制药组合物以及治疗细菌感染的方法。
• Linking Bisphosphonates to the Free Amino Groups in Fluoroquinolones: Preparation of Osteotropic Prodrugs for the Prevention of Osteomyelitis
  作者：Tom J. Houghton、Kelly S. E. Tanaka、Ting Kang、Evelyne Dietrich、Yanick Lafontaine、Daniel Delorme、Sandra S. Ferreira、Frederic Viens、Francis F. Arhin、Ingrid Sarmiento、Dario Lehoux、Ibtihal Fadhil、Karine Laquerre、Jing Liu、Valérie Ostiguy、Hugo Poirier、Gregory Moeck、Thomas R. Parr、Adel Rafai Far

  DOI：10.1021/jm801007z

  日期：2008.11.13

  Osteomyelitis is an infection located in bone and a notoriously difficult disease to manage, requiring frequent and heavy doses of systemically administered antibiotics. Targeting antibiotics to the bone after systemic administration may provide both greater efficacy of treatment and less frequent administration. By taking advantage, of the affinity of the bisphosphonate group for bone mineral, we have prepared a set of 13 bisphosphonated antibacterial prodrugs based on eight different linkers tethered to the free amino functionality on fluoroquinolone antibiotics. While all but one of the prodrugs were shown in vitro to be effective and rapid bone binders (over 90% in 1 h), only eight of them demonstrated the capacity to significantly regenerate the parent drug. In a rat model of the disease, a selected group of agents demonstrated their ability to prevent osteomyelitis when used in circumstances under which the parent drug had already been cleared and is thus inactive.
• PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
  申请人：Targanta Therapeutics Inc.

  公开号：EP1881974A2

  公开（公告）日：2008-01-30
• [EN] PHOSPHONATED FLUOROQUINOLONES, ANTIBACTERIAL ANALOGS THEREOF, AND METHODS FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS<br/>[FR] FLUOROQUINOLONES PHOSPHONEES, LEURS ANALOGUES ANTIBACTERIENS, ET METHODES PERMETTANT DE PREVENIR ET DE TRAITER DES INFECTIONS OSSEUSES ET ARTICULAIRES
  申请人：TARGANTA THERAPEUTICS INC

  公开号：WO2007017762A2

  公开（公告）日：2007-02-15

  [EN] The present invention relates to phosphonated fluoroquinolones, antibacterial analogs thereof, and methods of using such compounds. These compounds are useful as antibotics for prevention and/or the treatment of bone and joint infections, especially for the prevention and/or treatment of osteomyelitis.
  [FR] La présente invention se rapporte à des fluoroquinolones phosphonées, à des analogues antibactériens de celles-ci, et à des procédés d'utilisation de tels composés. Lesdits composés sont utiles en tant qu'antibiotiques destinés à prévenir et/ou à traiter des infections osseuses et articulaires, en particulier l'ostéomyélite.